BTIG reiterates Sophia Genetics stock rating on customer growth
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Stocks recover a chunk of their losses, still in the red on Middle East conflict Gold slips on stronger dollar; safe haven demand remains high amid Iran conflict Oil pares some gains as Trump says U.S. to escort tankers through Strait of Hormuz JPMorgan names winner and loser sectors from Iran conflict (South Africa Philippines Nigeria) BTIG reiterates Sophia Genetics stock rating on customer growth By Analyst Ratings Published 03/03/2026, 03:14 PM BTIG reiterates Sophia Genetics stock rating on customer growth 0 SOPH -8.55% Investing.com - BTIG maintained its Buy rating and $7.00 price target on Sophia Genetics SA (NASDAQ:SOPH) . The target aligns with the broader analyst consensus, where price targets range from $7 to $9, though InvestingPro analysis suggests the stock may be overvalued at its current price of $4.26. The firm noted the company is signing record numbers of new customers. SOPH is more than doubling the average contract value on newer deals signed, which is expected to drive up average selling prices. Dozens of customers are nearing their implementations of new SOPH applications, including the MSK ACCESS liquid biopsy. More than 70 customers are signed for this application, which would mark an inflection in revenue growth. BTIG said SOPH sees signs of a recovery building in biopharma after a difficult period. More clinical customers coming online at higher average selling prices will mark an inflection point in revenue and margin to SOPH, according to the firm. The company generated $73.3 million in revenue over the last twelve months with an impressive gross margin of 67.52%, though InvestingPro Tips note the company is not yet profitable. Investors can access a comprehensive Pro Research Report on SOPH, one of 1,400+ available reports offering expert analysis and actionable intelligence. The firm reiterated its Buy rating and $7 price target on the stock. In other recent news, SOPHiA GENETIC...
Read full article at source